Cross-sectional serologic assessment of immunity to poliovirus infection in high-risk areas of Northern India

Journal of Infectious Diseases

Volumn 210, Issue , 2014, Pages S243-S251

  Bahl, Sunil ^a   Estivariz, Concepcion F ^c   Sutter, Roland W ^a   Sarkar, Bidyut K ^a,d   Verma, Harish ^a   Jain, Vibhor ^a   Agrawal, Ashutosh ^a   Rathee, Mandeep ^a   Shukla, Hemant ^a   Pathyarch, Surendra K ^a   Sethi, Raman ^a   Wannemuehler, Kathleen A ^c   Jafari, Hamid ^a   Deshpande, Jagadish M ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Haffkine Institute for Training Research and Testing India   (India)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

bivalent oral poliovirus vaccine; immunization campaigns; monovalent oral poliovirus vaccine; oral poliovirus vaccine; poliovirus

Indexed keywords

NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ANTIBODY TITER; BLOOD ANALYSIS; BODY HEIGHT; BODY WEIGHT; CLINICAL ASSESSMENT; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNITY; IMMUNIZATION; INDIA; INFANT; INFECTION PREVENTION; MALE; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 1; POLIOVIRUS TYPE 2; POLIOVIRUS TYPE 3; REVIEW; SEROLOGY; SEROPREVALENCE; TREATMENT OUTCOME; VIRUS TRANSMISSION; BLOOD; EPIDEMIOLOGY; IMMUNOLOGY; NEWBORN; PROCEDURES; VACCINATION;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INDIA; INFANT; INFANT, NEWBORN; MALE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES; SEROEPIDEMIOLOGIC STUDIES; VACCINATION;

EID: 84910626152     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit492     Document Type: Review

References (32)

1. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-India, January 2006-September 2007. MMWR Morb Mortal Wkly Rep 2007; 56:1187-91.
2. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-India, January 2007-May 2009. MMWR Morb Mortal Wkly Rep 2009; 58:719-23.
3. Grassly NC, Fraser C,Wenger J, et al. New strategies for the elimination of polio from India. Science 2006; 314:1150-3.
4. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-India, January 2009-October 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1581-5.
5. Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010; 376:1682-8.
6. World Health Organization. Advisory Committee on Poliomyelitis Eradication: recommendations on the use of bivalent oral poliovirus vaccine types 1 and 3. Wkly Epidemiol Rec 2009; 84:289-300.
7. Grassly NC,Wenger J, Durrani S, et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 2007; 369:1356-62.
8. World Health Organization. Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, November 2009. Special consultation with pol io-infected countries and global management team partners, Geneva, 18-19 November 2009. Wkly Epidemiol Rec 2010; 85:1-11.
9. World Health Organization Multicentre Growth Reference Study Group. WHO child gr owth standards: length/height-for-Age, weightfor-Age, weight-for-length, weight-for-height and body mass indexfor-Age. Methods and development. Geneva:World Health Organization, 2006. http://www.who.int/childgrowth/standards/technical-report/en/i ndex.html. Accessed 24 October 2010.
10. World Health Organization. Assessing the iron status of populations. 2nd ed, including literature reviews. Geneva:World Health Organization, 2004.
11. Mother and child nutrition India. IFA supplementation-National nutritional anaemia prophylaxis program. http://motherchildnutrition.org/india/vitamin-A-ifa-supplementation.html. Accessed 27 September 2013.
12. Expanded Programme o n Immunization. Report of a WHO informal consultation on polio neutralizing antibody assays, Nashville, 5-6 December 1991. WHO/EPI/RD/91.3 Rev 1. Geneva: World Health Organization, 1991.
13. World Health Organizat ion Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia, Oman, and Thailand. J Infect Dis 1997; 175(sup pl 1):S215-27.
14. SAS/STAT user' s guide, version 6.4. 4th ed. Vol 1. Cary, NC: SAS Institute, 1989.
15. Research Triangle Institute. SUDAAN language manual, release 10.0. Research Triangle Park, NC: Research Triangle Institute, 2008.
16. Bieler GS, Brown GG, Williams RL, Brogan DJ. Estimating modeladjusted risks, risk differences, and risk ratios from complex survey data. Am J Epidemiol 2010; 171:618-23.
17. Estívariz CF, Jafari H, Sutter RW, et al. Immunogenicity of suppleme ntal doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis 2011; 12:128-35.
18. National Polio Surveillance Project. AFP and polio data. http://www.npspindia.org. Accessed 21 July 2011.
19. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010; 172: 1213-29.
20. John TJ. Antibody response of infants in tropics to five doses of oral polio vaccine. Br Med J 1976; 1:812.
21. Patriarca PA,Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926-39.
22. Posey DL, Linkins RW, Oliveria MJ, Monteiro D, Patriarca PA. The effect of diarrhea on oral poliovirus vaccine failure in Brazil. J Infect Dis 1997; 175 (suppl 1):S258-63.
23. Sabin AB. Strategies for elimination of poliomyelitis in different parts of the world with use of oral poliovirus vaccine. Rev Infect Dis 1984; 6(suppl 2):S391-6.
24. World Health Organization. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. J Infect Dis 1995; 171:1097-106.
25. Mahmoud AA, Imam IZ, Abozid SS, El Mished AM, Mitkis FA. The influence of bacill ary dysentery on the efficiency of oral poliovaccine in Egypt. Gaz Egypt Paediatr Assoc 1976; 24:82-91.
26. Myaux JA, Unicomb L, Besser RE, et al. Effect of diarrhea on the humoral response to oral polio vaccination. Pediatr Infect Dis J 1996; 15:204-9.
27. Sabin AB, Ramos Alvarez M, Alvarez Amezquita J, et al. Effects of the rapid collective immunization with oral live poliomyelitis vir us vaccine, of a population with widespread enteric infections with other viruses. Bol Ofic Sanit Panamer 1961; 51:104-12.
28. Reichler MR, Aslanian R, Lodhi ZH, et al. Evaluation of oral poliovirus vaccine delivery during the 1994 national immunization days in Pakistan. J Infect Dis 1997; 175 (suppl 1):S205-9.
29. Richardson G, Linkins RW, Eames MA, et al. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes. Bull World Health Organ 1995; 73:769-77.
30. Sutter RW,Pallansch MA,Sawyer LA,Cochi SL,Hadler SC. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci 1995 754: 289-99.
31. Fauveau V, Koenig MA, Wojtyniak B, Chakraborty JI. Impact of family planning and health services programme on adult female mortality. Health Policy Planning 1988; 3:271-9.
32. World Health Organization. Progress towards global interruption of wild poliovirus transmission, January 2011-March 2012. Wkly Epidemiol Rec 2012; 87:195-200.